Posted by Michael Wonder on 17 Oct 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma
15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial.
Merck today announced that Health Canada has approved Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score ≥ 1] as determined by a validated test.
Health Canada also approved Keytruda for the first-line treatment of metastatic or unresectable recurrent HNSCC in combination with platinum and 5-fluorouracil chemotherapy, in adult patients.
